Degenerative Disc Disease Drug Pipeline Analysis Report 2025

Degenerative disc disease (DDD) is a condition where spinal discs lose flexibility and height, causing pain and reduced mobility. It accounts for around 30% of people aged 30-50 years experiencing some degree of disc degeneration. There is a growing focus on developing advanced drug candidates to address pain and restore disc function. Recent advancements include regenerative medicine and biologics, which are expected to drive market growth. Moreover, the increasing prevalence of the condition and the rising demand for innovative degenerative disc disease therapeutic products are anticipated to fuel market expansion in the coming years.

Report Coverage

The Degenerative Disc Disease Drug Pipeline Insight Report by the publisher gives comprehensive insights into degenerative disc disease therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for degenerative disc disease. The degenerative disc disease report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The degenerative disc disease pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with degenerative disc disease treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to degenerative disc disease.

Degenerative Disc Disease Drug Pipeline Outlook

Degenerative disc disease (DDD) is a condition characterized by the gradual deterioration of spinal discs over time, resulting in pain and reduced flexibility. This degeneration occurs as the discs lose hydration and elasticity, which decreases their ability to cushion the vertebrae. Factors contributing to this process include aging, repetitive stress, and injuries.

Management of degenerative disc disease involves various treatments. Physical therapy helps strengthen the muscles that support the spine, thereby improving stability. Medications such as nonsteroidal anti-inflammatory drugs (NSAIDs) can help alleviate pain and inflammation. In more severe cases, surgical options like spinal fusion or artificial disc replacement may be considered to restore function and relieve discomfort.

Degenerative Disc Disease Epidemiology

Degenerative disc disease is a common condition affecting at least 30% of individuals aged 30 to 50 years. The highest estimated incidence is in Europe at 5.7 percent, with 5,668 cases per 100,000 people. In Japan, over one million people are affected annually, with approximately 200,000 requiring surgical intervention. Ongoing research is focusing on innovative therapies to address this growing healthcare challenge.

Degenerative Disc Disease - Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of degenerative disc disease drug candidates based on several segmentations, including:

By Phase

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

• Small Molecules
• Biologics
• Cell-based Therapies
• Monoclonal Antibodies
• Others

By Route of Administration

• Oral
• Parenteral
• Others

Degenerative Disc Disease - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total degenerative disc disease clinical trials.

Degenerative Disc Disease - Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the degenerative disc disease pipeline analysis include small molecules, biologics, cell-based therapies, monoclonal antibodies, and others. The degenerative disc disease report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for degenerative disc disease.

Degenerative Disc Disease Clinical Trials Therapeutic Assessment - Competitive Dynamics

The report for the degenerative disc disease drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed degenerative disc disease therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in degenerative disc disease clinical trials:

• Angitia Biopharmaceuticals
• Spine BioPharma, Inc.
• Kolon TissueGene, Inc.
• Mesoblast, Ltd.
• VIVEX Biologics, Inc.
• Kuros Biosurgery AG
• Locate Bio Pty Ltd.
• Creative Medical Technology Holdings Inc.

Degenerative Disc Disease Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for degenerative disc disease. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of degenerative disc disease drug candidates.

Drug: AGA111

AGA111, developed by Angitia Biopharmaceuticals, is indicated for degenerative disc disease. Currently in a Phase III clinical trial, it is being studied for its efficacy and safety following a single local injection into the intervertebral space in patients undergoing lumbar interbody fusion. The drug works by targeting specific signaling pathways to enhance spinal fusion and improve patient outcomes.

Drug: CELZ-201-DDT

CELZ-201-DDT, sponsored by Creative Medical Technology Holdings Inc., is currently in a Phase II clinical trial. The study is focused on evaluating the safety, tolerability, and efficacy of CELZ-201-DDT for treating chronic lower back pain caused by degenerative disc disease. This investigational drug uses AlloStem, an allogeneic perinatal cell-based therapy, aiming to repair tissues and improve blood supply through ultrasound-guided intramuscular injections.

Biological: TG-C

TG-C is an allogeneic cell and gene therapy developed by Kolon TissueGene, Inc. It combines primary human chondrocytes with cells engineered to express TGF-ß1, aiming to treat degenerative disc disease. It is a part of a Phase I study, which is evaluating the safety and tolerability of TG-C in subjects with chronic discogenic lumbar back pain due to degenerative disc disease.

Reasons To Buy This Report

The Degenerative Disc Disease Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for degenerative disc disease. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into degenerative disc disease collaborations, regulatory environments, and potential growth opportunities.

Key Questions Answered in the Degenerative Disc Disease - Pipeline Insight Report

• Which companies/institutions are leading the degenerative disc disease drug development?
• What is the efficacy and safety profile of degenerative disc disease pipeline drugs?
• Which company is leading the degenerative disc disease pipeline development activities?
• What is the current degenerative disc disease commercial assessment?
• What are the opportunities and challenges present in the degenerative disc disease drug pipeline landscape?
• What is the efficacy and safety profile of degenerative disc disease pipeline drugs?
• Which company is conducting major trials for degenerative disc disease drugs?
• Which companies/institutions are involved in degenerative disc disease collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in degenerative disc disease?

This product will be delivered within 3-5 business days.